Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

NTLA has been the topic of a number of other research reports. HC Wainwright dropped their price target on Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Citizens Jmp decreased their target price on shares of Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Wednesday, October 8th. Chardan Capital reduced their price target on shares of Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, Guggenheim cut shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, October 27th. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $18.43.

Intellia Therapeutics Trading Down 1.3%

NASDAQ:NTLA opened at $9.61 on Monday. The company has a 50-day moving average of $15.33 and a 200-day moving average of $12.59. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -2.25 and a beta of 2.13. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The business had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. During the same period in the previous year, the firm earned ($1.34) EPS. The business’s revenue for the quarter was up 51.6% on a year-over-year basis. On average, research analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In other news, CAO Michael P. Dube sold 1,871 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares in the company, valued at approximately $960,523.08. The trade was a 3.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds have recently made changes to their positions in NTLA. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics during the second quarter worth about $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Whipplewood Advisors LLC increased its position in shares of Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after purchasing an additional 3,447 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after purchasing an additional 1,655 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.